source
- Amylyx to seek FDA approval for avexitide after Phase 3 success in post-bariatric hypoglycemiaAmylyx announced plans to file a new drug application for avexitide, a GLP-1 receptor antagonist, after a Phase 3 trial showed reduction in serious hypoglycemia in patients who had gastric bypass s…
- Enveda reports promising Phase 1 data for oral drug that mimics exercise to preserve muscle during weight lossEnveda, a biotech based in Boulder, Colorado, announced Phase 1 results for its oral candidate ENV-308, a chemically engineered version of the metabolite lactate phenylalanine (lac-phe). The metabo…STAT · 2d agoPositive readoutPositive